-
Aegis Capital Downgrades Alcobra Following Q3 Results
Monday, November 17, 2014 - 6:19pm | 170Read More...On Monday, analysts at Aegis Capital downgraded shares of Alcobra Ltd (NASDAQ: ADHD) from Buy to Hold without a price target. Yi Chen stated, "In view of the uncertainty from the FDA as to whether Alcobra can submit an NDA with data from one additional Phase 3 adult ADHD trial and data...
-
Aegis Evaluates Chinese Bio Firms
Wednesday, December 12, 2012 - 10:34am | 536Read More...Aegis Capital Corporation today initiated coverage of four Chinese biotech and biomedical firms that are expected to perform well in the near future. Aegis initiated a 15-month price target of $12 per share for TrovaGene (Nasdaq: TROV), which at the time of the report was only valued at $4.61 per...
